Abstract
As the list of anti-tumor immunotherapy agents and the list of cancers treated by these novel agents grow, a subset of patients are experiencing immune-related adverse events as a result of prolonged stimulation of the immune system. Many different immune related adverse events including colitis, hepatitis, pneumonitis, thyroiditis, hypophysitis, and cutaneous reactions can result from blocking these inhibitory pathways. The full spectrum of cutaneous immune related adverse events secondary to checkpoint inhibitor therapy is still being defined. The reported varied presentations include lichenoid reactions and bullous pemphigoid, amongst others. We present a severe cutaneous reaction, a case of debilitating erosive lichenoid dermatitis. This case emphasizes both the wide range of possible cutaneous reactions and the potential severity of these reactions.
| Original language | English (US) |
|---|---|
| Article number | 13 |
| Journal | Dermatology Online Journal |
| Volume | 24 |
| Issue number | 4 |
| State | Published - Apr 1 2018 |
Fingerprint
Keywords
- Anti-PD- 1
- Anti-PD-L 1
- Checkpoint inhibitor
- Cutaneous reactions
- Immune related adverse events
- Lichenoid dermatitis lichenoid toxicity
ASJC Scopus subject areas
- Dermatology
Cite this
Debilitating erosive lichenoid interface dermatitis from checkpoint inhibitor therapy. / Davis, Michael J.; Wilken, Reason; Fung, Maxwell A; Tartar, Danielle.
In: Dermatology Online Journal, Vol. 24, No. 4, 13, 01.04.2018.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Debilitating erosive lichenoid interface dermatitis from checkpoint inhibitor therapy
AU - Davis, Michael J.
AU - Wilken, Reason
AU - Fung, Maxwell A
AU - Tartar, Danielle
PY - 2018/4/1
Y1 - 2018/4/1
N2 - As the list of anti-tumor immunotherapy agents and the list of cancers treated by these novel agents grow, a subset of patients are experiencing immune-related adverse events as a result of prolonged stimulation of the immune system. Many different immune related adverse events including colitis, hepatitis, pneumonitis, thyroiditis, hypophysitis, and cutaneous reactions can result from blocking these inhibitory pathways. The full spectrum of cutaneous immune related adverse events secondary to checkpoint inhibitor therapy is still being defined. The reported varied presentations include lichenoid reactions and bullous pemphigoid, amongst others. We present a severe cutaneous reaction, a case of debilitating erosive lichenoid dermatitis. This case emphasizes both the wide range of possible cutaneous reactions and the potential severity of these reactions.
AB - As the list of anti-tumor immunotherapy agents and the list of cancers treated by these novel agents grow, a subset of patients are experiencing immune-related adverse events as a result of prolonged stimulation of the immune system. Many different immune related adverse events including colitis, hepatitis, pneumonitis, thyroiditis, hypophysitis, and cutaneous reactions can result from blocking these inhibitory pathways. The full spectrum of cutaneous immune related adverse events secondary to checkpoint inhibitor therapy is still being defined. The reported varied presentations include lichenoid reactions and bullous pemphigoid, amongst others. We present a severe cutaneous reaction, a case of debilitating erosive lichenoid dermatitis. This case emphasizes both the wide range of possible cutaneous reactions and the potential severity of these reactions.
KW - Anti-PD- 1
KW - Anti-PD-L 1
KW - Checkpoint inhibitor
KW - Cutaneous reactions
KW - Immune related adverse events
KW - Lichenoid dermatitis lichenoid toxicity
UR - http://www.scopus.com/inward/record.url?scp=85048733248&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048733248&partnerID=8YFLogxK
M3 - Article
VL - 24
JO - Dermatology Online Journal
JF - Dermatology Online Journal
SN - 1087-2108
IS - 4
M1 - 13
ER -